KRAS and familial pancreatic carcinoma: Further immunotherapeutic efforts have utilized T-cell receptors engineered to specifically target oncogenic forms of KRAS to control tumor growth in pancreatic cancer models (152) In addition to direct targeting of RAS antigens, immunotherapeutic approaches have been explored in combination with inhibition of downstream RAS signaling elements.